Vir Biotechnology Announces Positive Phase 2 Data for Tobevibart & Elebsiran Combination in Chronic Hepatitis Delta Treatment.

Vir Biotechnology's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that a monthly dose of the combination of tobevibart and elebsiran achieved high rates of undetectable HDV RNA, including those with cirrhosis and high baseline HDV RNA. The combination showed favorable safety profile, ALT reductions over time, and robust and sustained HDV RNA target not detected. These data were presented at AASLD and published in the New England Journal of Medicine.